4SC was granted a patent related to its rheumatoid arthritis drug candidate, SC12267. The patent protects the DHODH inhibitor. SC 12267 is currently in Phase IIa trials.
In addition, the patent also covers further back-up substances related to SC12267, medical formulations, and the treatment of patients with SC12267. The patent will apply until 2020.
This expansion on 4SC’s patent portfolio, explains Ulrich Dauer, CEO, creates “the ideal conditions for a potential licensing partnership within the scope of this project."